What Is the Life Expectancy of Someone With Bronchiectasis?

There is no single life expectancy figure for bronchiectasis because the condition ranges enormously in severity, and outcomes depend on factors like lung function, infection history, how many flare-ups you have per year, and whether you have other lung diseases alongside it. What the research does show is that bronchiectasis modestly increases the risk of death compared to the general population, but many people with mild or well-managed disease live for decades. The gap between the best and worst outcomes is wide enough that talking about “the” life expectancy of bronchiectasis is misleading without knowing where someone falls on that spectrum.

What the Mortality Studies Actually Show

Bronchiectasis research does not typically report life expectancy in years the way you might see for cancer staging. Instead, studies track groups of patients over time and report how many died during the follow-up period. One long-term study found that roughly 30% of patients died over the course of follow-up, with age, lung function measures, and Pseudomonas aeruginosa infection all independently tied to higher mortality.¹ A separate prospective study with a median follow-up of about five years reported an overall mortality of about 20% among patients with non-cystic fibrosis bronchiectasis, with most of those deaths being respiratory-related.²

These numbers can sound alarming in isolation, but context matters. The patients in these studies were typically recruited from specialty clinics, meaning they were often sicker than the average person living with bronchiectasis in the community. People with mild disease who rarely see a lung specialist are underrepresented in these cohorts, which skews the mortality figures upward.

How Much Does Bronchiectasis Shorten Life Compared to the General Population?

A large population-matched study found that all-cause mortality was about 15% higher in people with bronchiectasis than in matched controls without the condition. The excess risk was most pronounced among elderly patients and men.³ Another study using a national database reported an adjusted mortality risk about 26% higher in the bronchiectasis group, with respiratory-related deaths roughly three-and-a-half times more common and lung cancer deaths similarly elevated.⁴

An increased risk of 15 to 26% over matched controls is meaningful but not catastrophic for most people. For perspective, the excess mortality associated with bronchiectasis alone is far smaller than what you see with advanced heart failure or many cancers. The problem is that bronchiectasis rarely exists by itself. When it overlaps with COPD, the picture changes dramatically.

The Factors That Matter Most for Prognosis

If you or someone you care about has bronchiectasis, the question “how long will I live?” really depends on a handful of key variables. These are the ones that consistently predict worse outcomes across multiple studies.

COPD Overlap

This is the single biggest modifier. In the five-year prospective study mentioned earlier, patients who had both bronchiectasis and COPD had a 55% mortality rate, compared to about 20% in the overall bronchiectasis group. On multivariate analysis, having concurrent COPD roughly doubled the risk of death.² If your bronchiectasis exists alongside COPD, managing both conditions aggressively matters far more than managing either one alone.

Lung Function

How well your lungs move air, measured by a standard breathing test, is one of the strongest predictors of how long you will live with bronchiectasis. Lower lung function at baseline consistently predicts worse outcomes. One study identified the percentage of predicted forced expiratory volume as an independent predictor of unfavorable outcomes even after accounting for age and other factors.⁵ This is why your lung doctor keeps ordering those breathing tests year after year. The trajectory of your lung function over time tells them more about your future than any single snapshot.

Infections and Bacterial Colonization

Pseudomonas aeruginosa gets a lot of attention in bronchiectasis because it is hard to eradicate and signals more advanced disease. Multiple studies have linked Pseudomonas to worse outcomes, though its independent contribution to mortality, once you account for disease severity, is debated. One prospective cohort found that Pseudomonas did not independently increase mortality on its own but roughly doubled the risk of death when combined with moderate- or high-risk comorbidities.⁶ Nontuberculous mycobacteria, another group of bugs that can colonize damaged airways, have also been linked to roughly a 56% higher mortality risk in a population survey.⁷

Exacerbation Frequency

Having frequent flare-ups, defined in one study as at least two per year or one requiring hospitalization, predicted mortality independently of initial disease severity.⁸ This finding matters because it means exacerbation prevention is not just about quality of life in the short term; it affects how long you live. Every hospitalization for an exacerbation carries its own risks, and the cumulative damage to the lungs accelerates the disease cycle.

How Much of the Lung Is Affected

The number of lobes involved on imaging independently predicted mortality in the five-year cohort, with each additional lobe increasing the hazard by about 53%.² Localized disease confined to one or two lobes has a fundamentally different prognosis than diffuse disease spread across both lungs.

Severity Scores That Predict Survival

Doctors have developed scoring systems to stratify bronchiectasis patients into risk categories. The two most studied are the Bronchiectasis Severity Index (BSI) and the FACED score (an acronym based on lung function, age, colonization, extent, and dyspnea). The BSI was designed to predict mortality and hospitalization, and in its validation it achieved strong predictive accuracy across multiple healthcare systems.⁹

In a head-to-head comparison over 19 years, both scores performed similarly for predicting five-year mortality. For 15-year mortality, the FACED score showed slightly better predictive power.¹⁰ A meta-analysis comparing the two found that the FACED score with a high-severity cutoff was more specific for predicting death, while the BSI was more sensitive at catching patients at risk.¹¹

These scores are useful for your clinical team but have limits. They tell you which risk category you fall into, not how many years you have left. A “low-risk” BSI score means your five-year survival odds are excellent. A “high-risk” score means closer monitoring and more aggressive treatment are warranted. If your doctor has calculated one of these scores for you, ask what category you fall into and what the score suggests about your trajectory.

How Bronchiectasis Actually Causes Death

Most deaths in bronchiectasis are respiratory in origin. In the five-year prospective cohort, 58% of deaths were directly respiratory-related.² The national database study found that both respiratory deaths and lung cancer deaths were roughly three-and-a-half times more common in people with bronchiectasis than in matched controls.⁴ The lung cancer connection is not fully understood but may reflect the chronic inflammation and structural changes in the airways that characterize the disease.

Pulmonary hypertension is another pathway to death that deserves attention. When bronchiectasis is severe enough to cause elevated blood pressure in the lung arteries, survival drops sharply. One study found that the five-year survival rate for bronchiectasis patients with pulmonary hypertension was roughly 63%, compared to about 96% for those without it.¹² Elevated pulmonary vascular resistance was independently associated with death even after adjusting for age and body weight.¹³ This complication is more likely in people with long-standing, severe disease and low oxygen levels.

Cystic Fibrosis Bronchiectasis Versus Non-CF Bronchiectasis

These two conditions share damaged, dilated airways, but they are different diseases with different trajectories. Among patients sick enough to be on the lung transplant waiting list, those with non-CF bronchiectasis had about a 30% lower risk of death than those with cystic fibrosis.¹⁴ The vast majority of what is discussed in this article applies to non-CF bronchiectasis, the form that develops after severe pneumonia, immune problems, or for unknown reasons. Cystic fibrosis has its own survival statistics, treatment protocols, and trajectory that are outside the scope here.

Treatments That Improve the Outlook

Life expectancy in bronchiectasis is not a fixed number handed down at diagnosis. It shifts with treatment. Several interventions have evidence behind them for reducing exacerbations and, in some cases, improving survival.

Long-Term Antibiotics

Azithromycin, a macrolide antibiotic with anti-inflammatory properties, is one of the best-studied interventions. A randomized trial found that over a year, fewer than half of patients on azithromycin had an exacerbation, compared to 80% in the placebo group.¹⁵ Another randomized trial found that the exacerbation rate dropped by more than 60% in the azithromycin group over six months of treatment.¹⁶ A recent meta-analysis confirmed that these benefits hold across both adult and pediatric populations, with no significant increase in adverse events compared to placebo.¹⁷ Because exacerbation frequency independently predicts mortality, reducing flare-ups is expected to extend life, though the trials themselves were not long enough to show a direct survival benefit.

Pulmonary Rehabilitation

Structured exercise programs supervised by physiotherapists are underused in bronchiectasis, but the survival data is promising. A propensity-matched analysis found that patients who underwent pulmonary rehabilitation had a 36% lower risk of death than those who did not.¹⁸ A systematic review of exercise training programs found improvements in walking distance and disease-specific quality of life after eight weeks, though these gains faded at six months, suggesting ongoing exercise is needed to maintain benefits.¹⁹ Airway clearance techniques, such as chest physiotherapy and mucus-clearing devices, are standard components of daily care and help reduce the mucus buildup that fuels the infection-inflammation cycle.

Surgery for Localized Disease

When bronchiectasis is confined to a specific part of the lung and is not responding to medical therapy, surgical removal of the affected lobe can be highly effective. In a 20-year review, over 90% of surgically treated patients had outcomes rated as excellent or improved, with no deaths during the operations.²⁰ Another series confirmed that complete resection of the affected segments produced the best results, with low complication rates.²¹ Surgery is not relevant for most patients because the disease is usually too widespread, but for the right candidate it can effectively cure the problem in that part of the lung.

Functional Fitness as a Survival Predictor

Beyond lab tests and scans, how well you can physically function says a lot about your prognosis. The six-minute walk test, a simple measure of how far you can walk in six minutes on a flat surface, independently predicted mortality in a bronchiectasis cohort even after adjusting for disease severity scores. Lower walking distance and lower oxygen levels during the walk both predicted a higher risk of death.²² This reinforces the case for staying as physically active as your lungs allow. Fitness is not just a quality-of-life issue; it tracks with survival.

Socioeconomic Factors and Access to Care

Bronchiectasis outcomes are not just about biology. Where you live, what resources you have, and whether you can access consistent specialist care all shape your prognosis. A study in New Zealand found that 70% of hospitalized bronchiectasis patients lived in the most deprived 20% of neighborhoods, and greater deprivation was associated with an eleven-fold increase in 12-month mortality after admission.²³ A 2024 epidemiology review highlighted that socioeconomic deprivation and limited access to healthcare are major drivers of both the prevalence and mortality of bronchiectasis globally, noting that Indigenous Australians face life expectancies over a decade shorter than non-Indigenous Australians, with respiratory disease playing a major role.²⁴

This disparity is not unique to bronchiectasis, but the disease is particularly sensitive to it. Bronchiectasis demands ongoing daily management: airway clearance, antibiotics when needed, monitoring for new infections, regular lung function testing, and sometimes intravenous treatment for severe exacerbations. People without consistent access to a pulmonologist, a physiotherapist, or even reliable transportation to appointments are at a measurable disadvantage. For many patients around the world, the biggest threat to their survival is not the disease itself but the gap between what treatment can do and what they can actually access.

Gender and Age Differences

Men with bronchiectasis tend to have worse mortality outcomes than women. The population-matched study found that the excess mortality risk was higher in men than in women, and higher in elderly patients than in younger ones.³ Some of this gap may be explained by differences in lung function at presentation. A study from northern China found that female patients generally had better baseline lung function than males, though women over 65 had a higher prevalence of Pseudomonas colonization.²⁵ The interplay between sex, age, smoking history, and comorbidities makes it difficult to isolate gender as a standalone risk factor, but the pattern of worse outcomes in older men is consistent across studies.

1
European Respiratory Journal. Mortality in bronchiectasis: a long-term study assessing the factors influencing survival
2
Respiratory Medicine. Mortality in non-cystic fibrosis bronchiectasis: A prospective cohort analysis
3
PubMed Central. Increased mortality in patients with non cystic fibrosis bronchiectasis with respiratory comorbidities
4
PubMed Central. Mortality risk and causes of death in patients with non-cystic fibrosis bronchiectasis
5
PubMed. Prognostic Factors in Adult Patients with Non-Cystic Fibrosis Bronchiectasis
6
PubMed Central. The contribution of Pseudomonas aeruginosa infection to clinical outcomes in bronchiectasis: a prospective cohort study
7
PubMed. Prevalence, risk factors and prognosis of nontuberculous mycobacterial infection among people with bronchiectasis: a population survey
8
PubMed. Prognostic Value of Frequent Exacerbations in Bronchiectasis: The Relationship With Disease Severity
9
American Journal of Respiratory and Critical Care Medicine. The Bronchiectasis Severity Index. An International Derivation and Validation Study
10
PubMed. Predicting mortality in bronchiectasis using bronchiectasis severity index and FACED scores: a 19-year cohort study
11
PubMed Central. Prognostic performance of the FACED score and bronchiectasis severity index in bronchiectasis: a systematic review and meta-analysis
12
Respiratory Medicine. Factors associated with pulmonary hypertension and long-term survival in bronchiectasis subjects
13
PubMed Central. Pulmonary vascular resistance predicts the mortality in patients with bronchiectasis-associated pulmonary hypertension
14
PubMed. Survival in Patients with Advanced Non-cystic Fibrosis Bronchiectasis Versus Cystic Fibrosis on the Waitlist for Lung Transplantation
15
JAMA. Effect of Azithromycin Maintenance Treatment on Infectious Exacerbations Among Patients With Non–Cystic Fibrosis Bronchiectasis
16
The Lancet. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBARC): a randomised, double-blind, placebo-controlled trial
17
PubMed Central. Efficacy of Azithromycin in Preventing Pulmonary Exacerbations Among Patients With Bronchiectasis: A Systematic Review and Meta-Analysis
18
American Journal of Respiratory and Critical Care Medicine. Association Between Initiation of Pulmonary Rehabilitation, Health Care Utilization and Survival Among Bronchiectasis Patients
19
Archives of Physical Medicine and Rehabilitation. Pulmonary Rehabilitation in Individuals With Non–Cystic Fibrosis Bronchiectasis: A Systematic Review
20
Revista Portuguesa de Pneumologia (English Edition). Surgical treatment of bronchiectasis: A review of 20 years of experience
21
PubMed Central. A long-term study assessing the factors influencing survival and morbidity in the surgical management of bronchiectasis
22
PubMed Central. The 6-minute walk test predicts mortality in a pulmonary nontuberculous mycobacteria-predominant bronchiectasis cohort
23
PubMed. Socioeconomic deprivation, readmissions, mortality and acute exacerbations of bronchiectasis
24
European Respiratory Review. Epidemiology of bronchiectasis
25
PubMed Central. Gender differences in clinical characteristics of patients with non-cystic fibrosis bronchiectasis in different age groups in northern China